Natera’s Solomon Moshkevich on How MRD Testing Pinpoints Cancer Recurrence
Natera’s Signatera molecular residual disease (MRD) test analyzes circulating tumor DNA to detect cancer recurrence earlier than traditional imaging or biopsies. Launched in 2019, the test has driven strong revenue growth and is now covered by Medicare for several solid‑tumor indications. Although only about half of oncologists use it regularly, the company expects broader adoption as evidence accumulates. Recent FDA approval of Signatera CDx as a companion diagnostic for bladder‑cancer immunotherapy highlights its expanding clinical role.
J&J Recalls Impella Heart Pumps After Patient Dies
Johnson & Johnson’s Abiomed unit recalled seven Impella CP Sets with SmartAssist after an internal review linked the devices to low purge pressure events that caused one patient death and three pump exchanges. The defect appeared in just 0.01 % of over...
Ōura to Add Blood Pressure Feature Following FDA Policy Change
Ōura introduced the Ring 5 smart ring and announced a suite of new health features to roll out in June. The updates include nighttime blood‑pressure trend monitoring, which reports pressure patterns without systolic/diastolic numbers, and a 30‑day view of breathing regularity....
Siemens Healthineers, AiM Team up; Procept Completes Study Enrollment
Siemens Healthineers and AiM Medical Robotics announced a collaboration to integrate AiM’s portable robotic neurosurgery platform with Siemens’ Magnetom MRI scanners, enabling MRI‑guided procedures such as deep‑brain stimulation and tumor ablation. AiM, which raised $8.1 million in a Series A round last...
Abbott Receives CE Mark for Dual Glucose-Ketone Sensor
Abbott has secured the European CE mark for Libre Duo, the first continuous sensor that measures both glucose and ketones. The system will debut in Europe this year with a 15‑day adult version and a 10‑day pediatric version for users as...
Ōura Files for IPO Amid Healthcare Push
Finnish wearables maker Oura has confidentially filed a draft registration statement to launch an initial public offering. The filing follows a $900 million funding round that was earmarked for expanding health‑monitoring capabilities. Oura recently secured FDA clearance to study blood‑pressure detection...
Beta Bionics to Launch Its First Insulin Patch Pump to Compete with Insulet
Beta Bionics announced it will debut its first insulin patch pump, called Mint, by the end of Q2 2027 pending FDA clearance. The three‑day wearable features a 200‑unit reservoir and blends reusable and disposable components, linking to the company’s adaptive dosing...
Medtronic to Buy SPR Therapeutics for About $650M
Medtronic announced a $650 million cash acquisition of SPR Therapeutics, a maker of a temporary peripheral nerve stimulation device for chronic pain. The Sprint system, cleared by the FDA in 2018, has logged 50,000 implants through 2025 and offers up to...
Medtronic Data Back Renal Denervation in the Long Term
Medtronic reported that two EuroPCR abstracts based on the global SYMPLICITY registry show its Symplicity Spyral renal denervation system delivers sustained blood‑pressure reductions over three years. One analysis of 787 patients with prior cardiovascular events recorded a 17.4 mmHg drop in office...
Endologix Buys Clot Removal System From Surmodics
Endologix announced the acquisition of the Pounce peripheral thrombectomy system from Surmodics for an undisclosed price. Pounce, cleared by the FDA in 2020 and expanded with a larger version in 2024, uses dual nitinol baskets and a funnel to mechanically...
Medtronic, BD Name New Leaders
Medtronic announced that Kweli Thompson, currently president of its cardiac rhythm management division, will become president of the company's neuroscience portfolio on June 1, succeeding Brett Wall, who will depart by Sept. 1 and resign from the MiniMed board in July. Scott Cundy, Medtronic’s...
Artivion Closes Endospan Buyout to Acquire Recently Approved Heart Device
Artivion completed its acquisition of Endospan by paying $131.3 million upfront for the Nexus Aortic Arch System, with up to $200 million in earn‑out payments tied to commercial success. The company estimates a $150 million annual U.S. addressable market for the minimally invasive,...
Boston Scientific Buys $1.5B Stake in TAVR Developer MiRus
Boston Scientific announced a $1.5 billion investment for a 34% equity stake in MiRus, the developer of a balloon‑expandable transcatheter aortic valve replacement (TAVR) system. The deal includes an exclusive option to acquire the remaining TAVR business for up to an...
Embecta Closes Owen Mumford Acquisition for up to $201M
Embecta closed its acquisition of UK‑based Owen Mumford for up to £150 million (about $201 million), shifting its focus from diabetes‑only products to a broader medical‑supplies portfolio. The deal includes a £100 million upfront payment and up to £50 million in performance‑based earn‑outs tied to...
Reinventing the Stethoscope and Cardiopulmonary Care
Eko Health, backed by Infineon, has launched the CORE 500 AI‑powered digital stethoscope, which pairs ultra‑low‑power PSoC 63 microcontrollers with advanced MEMS microphones to deliver real‑time heart‑sound analysis and three‑lead ECG. Clinical data from the TRICORDER trial show the device identifies heart...